Waverley Pharma WAVE.V · CAD

Its shares trade on TSX Venture under the ticker WAVE.V. It has been listed since 27 April 2017. In the fiscal year to 31 December 2025, it reported revenue of C$1.3m and a net loss of C$499,214. At that date it held total assets of C$1.2m and shareholders' equity of −C$2.6m.

Waverley Pharma, Inc. is a pharmaceutical company, which engages in the commercialization and development of oncology drugs. The company is headquartered in Winnipeg, Manitoba. The company went IPO on 2017-04-27. The firm is focused on the generic oncology injectable market in Europe, the United Kingdom, and North America. Its generic oncology product is bortezomib. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Its other generic oncology product, pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma. In addition to the development of pemetrexed and bortezomib, it also focuses on acquiring rights to six additional products for the United States market. The brands represented by these six generic products, referred to by the Company as WAV-103, WAV-104, WAV-105, WAV-106, WAV-107 and WAV-108. The company also sells products, including capecitabine, temozolomide, and erlotinib.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Albert FriesenChairman of the Board, since 2016
• Mr. Larry ThiessenPresident, Chief Executive Officer, Director, since 2020C$31,000
• Mr. Haaris UddinChief Financial OfficerC$30,500
• Mr. P. Marcus EnnsIndependent Director
• Mr. James KinleyIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.